Liver X receptors studied as a new class of cancer meds

Two researchers at the University of Houston say that recent work highlights the promise of liver X receptors, or LXRs, as a target for hard-to-treat cases of pancreatic cancer. Cancer biologist Chin-Yo Lin, an assistant professor with the UH Center for Nuclear Receptors and Cell Signaling, says there is now enough evidence to demonstrate that LXRs are a promising field for a variety of malignancies. "Our findings point to a class of receptors that can be precisely targeted by drug compounds and are expected to stimulate both basic and translational research on their functions and application as a drug target," Lin said. "Long-term goals are to develop additional drug compounds and clinical testing in human subjects, which will require several more years of research." Release

Suggested Articles

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.

Brigham and Women’s Hospital scientists linked a noncoding RNA to atherosclerosis in a discovery that could aid in the development of new heart drugs.